{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:21:20Z","timestamp":1762917680039},"reference-count":28,"publisher":"Impact Journals, LLC","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,6,14]]},"DOI":"10.18632\/oncotarget.8871","type":"journal-article","created":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T12:24:06Z","timestamp":1461327846000},"page":"36382-36394","source":"Crossref","is-referenced-by-count":14,"title":["Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR\/ABL axis"],"prefix":"10.18632","volume":"7","author":[{"given":"Xiaojuan","family":"Yang","sequence":"first","affiliation":[{"name":"The Hormel Institute, University of Minnesota, Austin, MN 55912, USA"},{"name":"Department of Biological Chemistry and Pharmacology, The Ohio State University, Columbus, OH 43210, USA"},{"name":"Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiuxia","family":"Pang","sequence":"additional","affiliation":[{"name":"The Hormel Institute, University of Minnesota, Austin, MN 55912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Shen","sequence":"additional","affiliation":[{"name":"The Hormel Institute, University of Minnesota, Austin, MN 55912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yan","sequence":"additional","affiliation":[{"name":"The Hormel Institute, University of Minnesota, Austin, MN 55912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai-Chu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry and Pharmacology, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University\/Collaborative Innovation Center of Biotherapy, Chengdu, 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujun","family":"Liu","sequence":"additional","affiliation":[{"name":"The Hormel Institute, University of Minnesota, Austin, MN 55912, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,4,20]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Kantarjian","year":"1999","journal-title":"The New England journal of medicine"},{"key":"2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrc3099","article-title":"Leukaemia: targeted therapy re-enABLed?","volume":"11","author":"Burgess","year":"2011","journal-title":"Nature reviews cancer"},{"key":"3","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1038\/onc.2010.67","article-title":"Thompson, Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming","volume":"29","author":"Sanchez","year":"2010","journal-title":"Oncogene"},{"key":"4","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/leu.2010.101","article-title":"BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase\/blast crisis CML patients","volume":"24","author":"Gambacorti-Passerini","year":"2010","journal-title":"Leukemia"},{"key":"5","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Talpaz","year":"2001","journal-title":"The New England journal of medicine"},{"key":"6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"Hochhaus","year":"2003","journal-title":"The New England journal of medicine"},{"key":"7","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Radich","year":"2003","journal-title":"The New England journal of medicine"},{"key":"8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd1579","article-title":"Strategies to overcome resistance to targeted protein kinase inhibitors","volume":"3","author":"Ullrich","year":"2004","journal-title":"Nature reviews drug discovery"},{"key":"9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0609.2008.01199.x","article-title":"Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients","volume":"82","author":"Larripa","year":"2009","journal-title":"European journal of haematology"},{"key":"10","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/ijc.23435","article-title":"Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl\/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification","volume":"122","author":"Ueda","year":"2008","journal-title":"International journal of cancer"},{"key":"11","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Sawyers","year":"2001","journal-title":"Science"},{"key":"12","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Melo","year":"2005","journal-title":"Cancer research"},{"key":"13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood-2003-12-4121","article-title":"Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr\/Abl-dependent and -independent mechanisms","volume":"104","author":"Grant","year":"2004","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1158\/0008-5472.CAN-09-0605","article-title":"Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors","volume":"69","author":"Khosravi-Far","year":"2009","journal-title":"Cancer research"},{"key":"15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.clml.2011.06.004","article-title":"Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase","volume":"11","author":"Cortes","year":"2011","journal-title":"Clinical lymphoma, myeloma & leukemia"},{"key":"16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11912-001-0016-5","article-title":"Liposomal encapsulated anthracyclines: new therapeutic horizons","volume":"3","author":"Muggia","year":"2001","journal-title":"Current oncology reports"},{"key":"17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1055-3290(96)80016-1","article-title":"Liposomal doxorubicin (Doxil)","volume":"7","author":"Porche","year":"1996","journal-title":"The Journal of the Association of Nurses in AIDS Care"},{"key":"18","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1182\/blood-2008-07-170589","article-title":"MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1","volume":"113","author":"Muthusamy","year":"2009","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ccr.2010.03.008","article-title":"Sp1\/NFkappaB\/HDAC\/miR-29b regulatory network in KIT-driven myeloid leukemia","volume":"17","author":"Maharry","year":"2010","journal-title":"Cancer Cell"},{"key":"20","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood-2007-08-110171","article-title":"Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1\/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia","volume":"111","author":"Klisovic","year":"2008","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.leu.2404270","article-title":"Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients","volume":"20","author":"Seifarth","year":"2006","journal-title":"Leukemia"},{"key":"22","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/sj.leu.2402309","article-title":"Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype","volume":"15","author":"McKenna","year":"2001","journal-title":"Leukemia"},{"key":"23","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","article-title":"Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine","volume":"107","author":"Becker","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"24","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1182\/blood-2012-03-413898","article-title":"Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia","volume":"119","author":"Byrd","year":"2012","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3390\/cancers3011426","article-title":"The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer","volume":"3","author":"Gray","year":"2011","journal-title":"Cancers"},{"key":"26","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/JTO.0b013e3181cee36e","article-title":"A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602)","volume":"5","author":"Vokes","year":"2010","journal-title":"Journal of thoracic oncology"},{"key":"27","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/leu.2015.56","article-title":"AML1\/ETO cooperates with HIF1alpha to promote leukemogenesis through DNMT3a transactivation","volume":"29","author":"Deng","year":"2015","journal-title":"Leukemia"},{"key":"28","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1021\/ac00009a010","article-title":"Determination of boron in tissues and cells using direct-current plasma atomic emission spectroscopy","volume":"63","author":"Anisuzzaman","year":"1991","journal-title":"Analytical chemistry"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.8871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T20:41:29Z","timestamp":1589229689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.8871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,20]]},"references-count":28,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2016,6,14]]}},"alternative-id":["8871","27144331"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.8871","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,20]]}}}